In today’s fast-moving biotech world, CDMOs have become essential strategic partners. With complex CGT pipelines and growing regulatory scrutiny, biotechs depend on CDMOs for GMP-grade manufacturing, process development, and quality assurance. These partnerships help reduce infrastructure investment, mitigate risk, and speed up clinical progress. The result is a powerful ecosystem whe... https://xellera.livejournal.com/4599.html